Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.

Nesbitt H, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ.

Prostate. 2017 Nov;77(15):1539-1547. doi: 10.1002/pros.23434. Epub 2017 Sep 24.

PMID:
28944496
2.

RGD-Binding Integrins in Head and Neck Cancers.

Ahmedah HT, Patterson LH, Shnyder SD, Sheldrake HM.

Cancers (Basel). 2017 May 26;9(6). pii: E56. doi: 10.3390/cancers9060056. Review.

3.

Nipple aspirate fluid-A liquid biopsy for diagnosing breast health.

Shaheed SU, Tait C, Kyriacou K, Mullarkey J, Burrill W, Patterson LH, Linforth R, Salhab M, Sutton CW.

Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201700015. Epub 2017 Jun 26.

4.

Host-guest kinetic interactions between HP-β-cyclodextrin and drugs for prediction of bitter taste masking.

Guo Z, Wu F, Singh V, Guo T, Ren X, Yin X, Shao Q, York P, Patterson LH, Zhang J.

J Pharm Biomed Anal. 2017 Jun 5;140:232-238. doi: 10.1016/j.jpba.2017.03.042. Epub 2017 Mar 20.

PMID:
28365517
5.
6.

Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.

Nesbitt H, Byrne NM, Williams SN, Ming L, Worthington J, Errington RJ, Patterson LH, Smith PJ, McKeown SR, McKenna DJ.

Clin Cancer Res. 2017 Apr 1;23(7):1797-1808. doi: 10.1158/1078-0432.CCR-16-1361. Epub 2016 Oct 3.

7.

An optimised assay for quantitative, high-throughput analysis of polysialyltransferase activity.

Elkashef SM, Sutherland M, Patterson LH, Loadman PM, Falconer RA.

Analyst. 2016 Oct 21;141(20):5849-5856. Epub 2016 Aug 12.

PMID:
27517096
8.

The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models.

Hussain N, Connah D, Ugail H, Cooper PA, Falconer RA, Patterson LH, Shnyder SD.

Sci Rep. 2016 Aug 5;6:31136. doi: 10.1038/srep31136.

9.

Rational Development of Novel Activity Probes for the Analysis of Human Cytochromes P450.

Sellars JD, Skipsey M, Sadr-Ul-Shaheed, Gravell S, Abumansour H, Kashtl G, Irfan J, Khot M, Pors K, Patterson LH, Sutton CW.

ChemMedChem. 2016 Jun 6;11(11):1122-8. doi: 10.1002/cmdc.201600134. Epub 2016 May 6.

PMID:
27154431
10.

A novel Lozenge gene in silkworm, Bombyx mori regulates the melanization response of hemolymph.

Xu M, Wang X, Tan J, Zhang K, Guan X, Patterson LH, Ding H, Cui H.

Dev Comp Immunol. 2015 Nov;53(1):191-8. doi: 10.1016/j.dci.2015.07.001. Epub 2015 Jul 9.

PMID:
26164197
11.

Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity.

Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA.

Mol Pharm. 2014 Apr 7;11(4):1294-300. doi: 10.1021/mp400760b. Epub 2014 Mar 27.

PMID:
24641451
12.

Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.

Sheldrake HM, Patterson LH.

J Med Chem. 2014 Aug 14;57(15):6301-15. doi: 10.1021/jm5000547. Epub 2014 Mar 7. Review.

PMID:
24568695
13.

Synthesis of a pseudo-disaccharide library and its application to the characterisation of the heparanase catalytic site.

Vinader V, Haji-Abdullahi MH, Patterson LH, Afarinkia K.

PLoS One. 2013 Nov 18;8(11):e82111. doi: 10.1371/journal.pone.0082111. eCollection 2013.

14.

Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists.

Vinader V, Ahmet DS, Ahmed MS, Patterson LH, Afarinkia K.

PLoS One. 2013 Oct 18;8(10):e78744. doi: 10.1371/journal.pone.0078744. eCollection 2013.

15.

Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration.

Al-Saraireh YM, Sutherland M, Springett BR, Freiberger F, Ribeiro Morais G, Loadman PM, Errington RJ, Smith PJ, Fukuda M, Gerardy-Schahn R, Patterson LH, Shnyder SD, Falconer RA.

PLoS One. 2013 Aug 9;8(8):e73366. doi: 10.1371/journal.pone.0073366. eCollection 2013.

16.

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Ingelman-Sundberg M, Patterson LH, Pors K.

J Med Chem. 2013 Aug 8;56(15):6273-7. doi: 10.1021/jm4000209. Epub 2013 Jul 26.

PMID:
23844629
17.

NCAM polysialylation during adherence transitions: live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7.

Smith PJ, Furon E, Wiltshire M, Chappell S, Patterson LH, Shnyder SD, Falconer RA, Errington RJ.

Cytometry A. 2013 Jul;83(7):659-71. doi: 10.1002/cyto.a.22306. Epub 2013 May 28.

18.

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.

Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M.

Clin Cancer Res. 2013 Jun 1;19(11):2952-61. doi: 10.1158/1078-0432.CCR-13-0238. Epub 2013 Apr 15.

19.

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH.

Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1.

20.

Polysialyltransferase: a new target in metastatic cancer.

Falconer RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH.

Curr Cancer Drug Targets. 2012 Oct;12(8):925-39. Review.

PMID:
22463390
21.

Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids.

McMahon KM, Volpato M, Chi HY, Musiwaro P, Poterlowicz K, Peng Y, Scally AJ, Patterson LH, Phillips RM, Sutton CW.

J Proteome Res. 2012 May 4;11(5):2863-75. doi: 10.1021/pr2012472. Epub 2012 Mar 30.

PMID:
22416669
22.

Minor structural modifications to alchemix influence mechanism of action and pharmacological activity.

Abdallah QM, Phillips RM, Johansson F, Helleday T, Cosentino L, Abdel-Rahman H, Etzad J, Wheelhouse RT, Kiakos K, Bingham JP, Hartley JA, Patterson LH, Pors K.

Biochem Pharmacol. 2012 Jun 1;83(11):1514-22. doi: 10.1016/j.bcp.2012.02.017. Epub 2012 Mar 1.

PMID:
22387433
23.

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

Sutherland M, Gordon A, Shnyder SD, Patterson LH, Sheldrake HM.

Cancers (Basel). 2012 Oct 26;4(4):1106-45. doi: 10.3390/cancers4041106.

24.

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.

Pors K, Loadman PM, Shnyder SD, Sutherland M, Sheldrake HM, Guino M, Kiakos K, Hartley JA, Searcey M, Patterson LH.

Chem Commun (Camb). 2011 Nov 28;47(44):12062-4. doi: 10.1039/c1cc15638a. Epub 2011 Oct 14.

PMID:
22002321
25.

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

Veiga JP, Cooper PA, Pors K, Patterson LH, Bibby MC, Shnyder SD.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):226-32. doi: 10.1016/j.vascn.2011.04.006. Epub 2011 Apr 30.

PMID:
21569858
26.

An agarose spot chemotaxis assay for chemokine receptor antagonists.

Vinader V, Al-Saraireh Y, Wiggins HL, Rappoport JZ, Shnyder SD, Patterson LH, Afarinkia K.

J Pharmacol Toxicol Methods. 2011 Nov-Dec;64(3):213-6. doi: 10.1016/j.vascn.2011.01.004. Epub 2011 Feb 1.

PMID:
21292017
27.

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH.

Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27.

28.

Improved preparation and detection of cytochrome P450 isoforms using MS methods.

Sutton CW, Sutherland M, Shnyder S, Patterson LH.

Proteomics. 2010 Jan;10(2):327-31. doi: 10.1002/pmic.200900489.

PMID:
19902426
29.

Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry.

Seibert C, Davidson BR, Fuller BJ, Patterson LH, Griffiths WJ, Wang Y.

J Proteome Res. 2009 Apr;8(4):1672-81. doi: 10.1021/pr800795r.

30.

Function and antagonism of beta3 integrins in the development of cancer therapy.

Sheldrake HM, Patterson LH.

Curr Cancer Drug Targets. 2009 Jun;9(4):519-40. Review.

PMID:
19519320
31.

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.

Steward WP, Middleton M, Benghiat A, Loadman PM, Hayward C, Waller S, Ford S, Halbert G, Patterson LH, Talbot D.

Ann Oncol. 2007 Jun;18(6):1098-103. Epub 2007 Apr 17.

PMID:
17442658
32.
33.

Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using 18O stable isotope labeling.

Lane CS, Wang Y, Betts R, Griffiths WJ, Patterson LH.

Mol Cell Proteomics. 2007 Jun;6(6):953-62. Epub 2007 Feb 11.

34.

Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides.

Pors K, Shnyder SD, Teesdale-Spittle PH, Hartley JA, Zloh M, Searcey M, Patterson LH.

J Med Chem. 2006 Nov 30;49(24):7013-23.

PMID:
17125254
35.

Stereoselectivity, sequence specificity and mechanism of action of the azinomycin epoxide.

David-Cordonnier MH, Casely-Hayford M, Kouach M, Briand G, Patterson LH, Bailly C, Searcey M.

Chembiochem. 2006 Nov;7(11):1658-61. No abstract available.

PMID:
16991169
36.

Spectral analysis of the DNA targeting bisalkylaminoanthraquinone DRAQ5 in intact living cells.

Njoh KL, Patterson LH, Zloh M, Wiltshire M, Fisher J, Chappell S, Ameer-Beg S, Bai Y, Matthews D, Errington RJ, Smith PJ.

Cytometry A. 2006 Aug 1;69(8):805-14.

37.

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T.

Cancer Gene Ther. 2006 Jun;13(6):598-605.

PMID:
16410820
38.
39.

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.

Pors K, Plumb JA, Brown R, Teesdale-Spittle P, Searcey M, Smith PJ, Patterson LH.

J Med Chem. 2005 Oct 20;48(21):6690-5.

PMID:
16220985
40.

Design and synthesis of a DNA-crosslinking azinomycin analogue.

Casely-Hayford MA, Pors K, James CH, Patterson LH, Hartley JA, Searcey M.

Org Biomol Chem. 2005 Oct 7;3(19):3585-9. Epub 2005 Sep 5.

PMID:
16172698
41.

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR.

J Gene Med. 2005 Jul;7(7):851-9.

PMID:
15712360
42.

Truncated azinomycin analogues intercalate into DNA.

Casely-Hayford MA, Pors K, Patterson LH, Gerner C, Neidle S, Searcey M.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):653-6.

PMID:
15664831
43.

Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells.

Errington RJ, Ameer-Beg SM, Vojnovic B, Patterson LH, Zloh M, Smith PJ.

Adv Drug Deliv Rev. 2005 Jan 2;57(1):153-67. Review.

PMID:
15518927
44.

Resistance in cancer: a target for drug discovery.

Searcey M, Patterson LH.

Curr Med Chem Anticancer Agents. 2004 Sep;4(5):457-60. Review.

PMID:
15379703
45.

Identification of cytochrome P450 enzymes in human colorectal metastases and the surrounding liver: a proteomic approach.

Lane CS, Nisar S, Griffiths WJ, Fuller BJ, Davidson BR, Hewes J, Welham KJ, Patterson LH.

Eur J Cancer. 2004 Sep;40(14):2127-34.

PMID:
15341988
46.
47.

Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.

Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH.

J Med Chem. 2004 Mar 25;47(7):1856-9.

PMID:
15027879
48.

Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer.

Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA, Patterson LH.

Mol Cancer Ther. 2003 Jul;2(7):607-10.

49.

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T.

Cancer Gene Ther. 2003 Jan;10(1):40-8.

PMID:
12489027
50.

Supplemental Content

Loading ...
Support Center